WESTMINSTER, Colo., Aug. 3, 2015
(GLOBE NEWSWIRE) --
Despite warnings from scientists who
have shown unquestionable data that Earth climate has been changing due to
human activities, governments and multinational corporations for years have
denied scientific evidences. MAP infection in cattle draws many similarities
with global warming. Despite the fact that MAP has been linked to several human
diseases, governments, the cattle and dairy industry have continued to ignore
scientific data and have not implemented any credible programs to control MAP
infection. In the meantime, herd prevalence of MAP infection in cattle
worldwide has reached alarming levels. More than 90% of dairy herds in
the US are infected. In the UK, 50% of dairy herds are infected with MAP.
A recent report from the Advisory Committee on Dangerous Pathogens (ACDP), a
scientific advisory board of the UK Government, concluded that MAP potential
for human infection exist and is not limited to Chron's Disease (CD). The
ACDP report points out that genome analysis have suggested an association
between MAP and several other inflammatory diseases besides CD.
These diseases
are:
•
Irritable
Bowel Syndrome
•
Type
1 Diabetes Mellitus
•
Multiple
Sclerosis
•
Parkinson's
Disease
•
Autism
The ACDP reports concluded that
"it is therefore possible that human effects of MAP exposure and infection
extend beyond just CD." Additionally, the ACDP report states "with
the advent of new and improved methods to detect viable MAP in milk and dairy
products, there is new evidence of higher levels of viable MAP than previously
believed in processed dairy products, in particular, in infant milk which is
consumed by the most susceptible sector of the population."
Dr. Tony Milici, Chairman & CEO
of GeneThera (OTC: GTHR) commented "It is quite clear from the
ACDP report and a large number of studies that the risk of MAP contamination of
milk and dairy products poses to the general population; particularly, children
and young adults, it can no longer be underestimated. Dairies and baby formula
producers need to implement large scale testing programs to control MAP
contamination in milk and certify that MAP-free milk is used for baby food
production."
GeneThera has spent several years
developing state-of-the-art technology to test milk products using advanced
integrated laboratory robotic platforms that allow the detection of
Mycobacterium Paratuberculosis in a highly sensitive and fast process. A
single integrated robotic system is capable to process over two thousand
samples daily with minimum human intervention. This automated platform provides
GeneThera with a standardized system that can be serially duplicated, readily
deployed, and supported across the globe to meet the growing needs of the
worldwide dairy industry. By standardizing on a flexible, easy to use robotic
platform, GeneThera will be able to meet its goals of building a global network
of labs that will test and communicate results to food producers in real time,
improving animal health and food safety.
About GeneThera, Inc.
GeneThera, Inc. is a molecular
biotechnology company located in Westminster, Colorado. The Company's
proprietary diagnostic solution is based on a genetic expression assay, GES and
Johne's disease management system, HERDCHECK™, designed to function on a highly
automated PCR platform. This platform enables GeneThera to offer tests that are
presently not available from other technologies. The GES and HERDCHECK™ systems
are designed for a host of individual diseases, the current priority being
Johne's disease.
This press release contains
forward-looking statements, which are made pursuant to the Safe-Harbor
provisions of the Private Securities Litigation Reform Act of 1995. Words
such as "intends," "believes," and similar expressions
reflecting something other than historical fact are intended to identify forward-looking
statements, but are not the exclusive means of identifying such statements.
These forward-looking statements involve a number of risks and uncertainties,
including the timely development and market acceptance of products and
technologies, the ability to secure additional sources of finance, the ability
to reduce operating expenses, and other factors described in the Company's
filings with the Securities and Exchange Commission. The actual results that
the Company achieves may differ materially from any forward-looking statement
due to such risks and uncertainties. The Company undertakes no obligation to
revise or update any forward-looking statements in order to reflect events or
circumstances that may arise after the date of this release.
CONTACT:
Tony Milici MD, Ph.D.
GeneThera Inc.
303 439-2085
http://www.einpresswire.com/article/279217635/mycobacterium-avium-paratuberculosis-map-infection-the-global-warming-of-the-cattle-industry
No comments:
Post a Comment